Product Overview

Vysov XR 100 Mg is a prescription medication that contains vildagliptin 100 mg, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used in the management of type 2 diabetes mellitus. Manufactured by Cipla Limited, each strip contains 15 film‑coated tablets that provide consistent daily dosing. The product is packaged in several strengths, including 60, 120, and 240 tablets, to suit individual treatment plans. Shipping typically takes between six and fifteen days, depending on the destination. This overview introduces the key attributes of Vysov XR, including its indication, strength, and manufacturer, setting the stage for a deeper look at its clinical use and patient‑focused information.

What is Vysov XR 100 Mg (Vildagliptin)

Vildagliptin, the active ingredient in Vysov XR, belongs to a class of antidiabetic agents that enhance the activity of incretin hormones. By inhibiting the DPP‑4 enzyme, vildagliptin slows the breakdown of glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP), leading to improved insulin secretion and reduced glucagon release when blood glucose levels rise. The “XR” designation denotes an extended‑release formulation designed to maintain steady plasma concentrations throughout the day, allowing once‑daily administration. Clinically, Vysov XR is indicated for adults with type 2 diabetes who require additional glycemic control, particularly when diet and exercise alone are insufficient.

Uses and Benefits

The primary use of Vysov XR 100 Mg is to lower blood glucose levels in patients with type 2 diabetes, helping to achieve target HbA1c values recommended by health authorities such as the NIH and the American Diabetes Association. Because it is a glucose‑dependent medication, it has a low risk of causing hypoglycemia when used alone, making it a suitable option for many patients who cannot tolerate sulfonylureas. Additional benefits include modest weight neutrality, which is advantageous for patients aiming to manage obesity alongside diabetes, and a favorable renal safety profile when dosing is adjusted for moderate kidney impairment. The extended‑release nature of the tablet simplifies the dosing schedule, improving adherence and reducing the likelihood of missed doses, which is a common challenge in chronic disease management.

How It Works

Vildagliptin exerts its antidiabetic effect by selectively binding to the DPP‑4 enzyme located on the surface of endothelial cells and immune cells. This binding prevents the enzymatic cleavage of incretin hormones, thereby preserving their activity and enhancing the pancreatic β‑cell response to elevated glucose. The cascade of events includes increased glucose‑dependent insulin release, decreased glucagon secretion, and slower gastric emptying, all of which collectively contribute to reduced post‑prandial glucose spikes. Pharmacokinetic studies show that the extended‑release formulation delivers a steady release of vildagliptin over approximately 24 hours, resulting in consistent plasma concentrations and sustained therapeutic effect. The drug is metabolized primarily through hydrolysis and excretion in the feces, with minimal renal elimination, which informs dosing adjustments for patients with impaired renal function.

Dosage Guidelines

For most adult patients, the recommended starting dose of Vysov XR 100 Mg is one tablet taken orally once daily, with or without food. The dose may be adjusted based on individual glycemic response, tolerability, and renal function. In patients with moderate renal impairment (estimated glomerular filtration rate 30‑89 mL/min/1.73 m²), the same once‑daily dose is generally appropriate. However, in those with severe renal impairment (eGFR <30 mL/min/1.73 m²) or end‑stage renal disease, the dose should be reduced to 50 mg once daily, or the medication should be avoided altogether. It is important to follow the prescribing clinician’s instructions and to monitor blood glucose regularly. Patients should not crush or split the tablet, as the extended‑release coating is integral to the drug’s pharmacokinetics. For comprehensive prescribing information, refer to the FDA label FDA.

Side Effects

Like all medications, Vysov XR may cause adverse effects, although most are mild and transient. The most commonly reported side effects include nasopharyngitis, urinary tract infections, and headache. Less frequent but clinically significant events can involve pancreatitis, severe joint pain, or hypersensitivity reactions such as rash and itching. Rarely, elevated liver enzymes have been observed, necessitating periodic liver function monitoring in high‑risk patients. If any sign of an allergic reaction, persistent fever, or unexplained muscle pain occurs, patients should seek medical attention promptly. It is also advisable to report any new or worsening symptoms to the prescribing healthcare provider, as dose adjustments or alternative therapies may be required. For detailed safety data, consult the NIH’s drug information portal NIH.

Warnings and Precautions

Vysov XR is contraindicated in individuals with known hypersensitivity to vildagliptin or any component of the formulation. It should not be used to treat type 1 diabetes or for the treatment of diabetic ketoacidosis. Caution is advised in patients with a history of pancreatitis, severe renal disease, or hepatic impairment, as these conditions may increase the risk of adverse events. Concomitant use with strong CYP3A4 inhibitors or inducers may alter drug levels and should be discussed with a clinician. Alcohol consumption should be limited, as excessive intake can exacerbate hyperglycemia. Pregnant or breastfeeding women should only use Vysov XR if the potential benefit justifies the potential risk, and they must consult their obstetric provider. Patients are encouraged to maintain regular follow‑up appointments to assess glycemic control, renal function, and overall health. For official prescribing information, see the drug label on Drugs.com.

Frequently Asked Questions

1. What is the difference between Vysov XR and immediate‑release vildagliptin?

Vysov XR uses an extended‑release matrix that delivers a steady 100 mg dose over 24 hours, allowing once‑daily administration. Immediate‑release formulations require twice‑daily dosing and may produce fluctuating drug levels, which can affect glycemic control and adherence.

2. Can Vysov XR be taken with other antidiabetic medications?

Yes, Vysov XR can be combined with metformin, sulfonylureas, or insulin, but dose adjustments may be necessary to avoid hypoglycemia. When used with insulin or sulfonylureas, clinicians typically reduce the accompanying medication dose to minimize the risk of low blood sugar.

3. How long does it take to see a reduction in HbA1c after starting Vysov XR?

Clinical studies show that a measurable decrease in HbA1c can be observed within 12 weeks of consistent daily use, although the full effect may take up to 24 weeks as steady‑state drug concentrations are achieved.

4. Is Vysov XR safe for patients with kidney problems?

Vysov XR can be used in patients with moderate renal impairment without dose adjustment, but in severe renal disease (eGFR <30 mL/min/1.73 m²) the dose should be reduced to 50 mg daily or avoided altogether, depending on the clinician’s judgment.

5. Where can I find more detailed prescribing information?

Comprehensive prescribing details, including contraindications, drug interactions, and adverse reaction rates, are available on the FDA’s drug label page, the NIH’s medication database, and reputable pharmacy sites such as Drugs.com.

Related Products

• Misoprost 600 mcg (Misoprostol)
• Misoprost (Misoprostol)
• Misoprost 200 mcg (Misoprostol)
• Misoprostol 600 mcg (Generic)
• Misoprostol 200 mcg (Generic)
• Pantosec D SR (Pantoprazole/Domperidone)
• Pantosec D 50 Mg (Pantoprazole/Domperidone)
• Rabicip 10 mg (Rabeprazole)
• Rabicip (Rabeprazole)
• Pantosec 40 mg (Pantoprazole)
• Rabicip 20 mg (Rabeprazole)
• Rabeprazole 20 mg (Generic)